Tag: efficacy
PhaseBio poised to make rapid strides in the Anti-Coagulant Reversal Market
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April 2019....
New Drugs show promise in curbing the Gonorrhea Menace
Gonorrhoea, caused by a bacterial pathogen N. gonorrhoea, is the second most commonly reported sexually transmitted disease in the U.S alone. The data made available...
We are looking for talented interns to learn and help investors find valuable companies.